Related Experiment Videos
The economic impact of hypertension
1Department of Preventive Medicine, Rush Medical College of Rush University, Rush-Presbyterian-St Lukes Medical Center, Chicago, IL 60612, USA. welliott@rush.edu
Insights
High blood pressure affects millions, with poor control increasing cardiovascular risks. Effective hypertension management is crucial for reducing health costs and preventing serious conditions like stroke and heart failure.
Area of Science:
- Cardiovascular Medicine
- Public Health
- Health Economics
Background:
- Hypertension is a prevalent chronic condition, yet a significant majority of affected American adults do not achieve target blood pressure control (<140/90 mm Hg).
- Inadequate blood pressure control elevates the risk of severe cardiovascular events and incurs substantial medical, economic, and human costs.
- Challenges in diagnosis, treatment adherence, and lifestyle modifications impede effective hypertension management for both healthcare providers and patients.
Purpose of the Study:
- To highlight the critical need for improved hypertension management strategies.
- To underscore the significant cardiovascular risks associated with uncontrolled high blood pressure.
- To emphasize the economic benefits and cost savings achievable through effective antihypertensive treatment.
Main Methods:
- Review of current challenges in hypertension diagnosis and treatment.
- Analysis of patient adherence issues and barriers to lifestyle changes.
- Examination of pharmacoeconomic data on antihypertensive therapies and healthcare expenditures.
Main Results:
- Only 34% of American adults with hypertension achieve controlled blood pressure levels, leaving two-thirds at increased cardiovascular risk.
- Effective blood pressure lowering significantly reduces cardiovascular morbidity and mortality, as demonstrated in clinical trials.
- Optimizing hypertension management through pharmacoeconomic strategies can lead to substantial healthcare cost savings.
Conclusions:
- Achieving blood pressure goals is attainable and essential for reducing cardiovascular disease burden.
- Antihypertensive treatment offers significant potential for cost savings by preventing costly secondary conditions like stroke and heart failure.
- Pharmacoeconomic analyses are vital for optimizing hypertension management strategies and resource allocation.
Abstract:
High blood pressure is the most common chronic medical problem prompting visits to primary health care providers, yet it is estimated that only 34% of the 50 million American adults with hypertension have their blood pressure controlled to a level of <140/90 mm Hg. Thus, about two thirds of Americans with hypertension are at increased risk for cardiovascular events. The medical, economic, and human costs of untreated and inadequately controlled high blood pressure are enormous. Adequate management of hypertension can be hampered by inadequacies in the diagnosis, treatment, and/or control of high blood pressure. Health care providers face many obstacles to achieving blood pressure control among their patients, including a limited ability to adequately lower blood pressure with monotherapy and a typical reluctance to increase therapy (either in dose or number of medications) to achieve blood pressure goals. Patients also face important challenges in adhering to multidrug regimens and accepting the need for therapeutic lifestyle changes. Nonetheless, the achievement of blood pressure goals is possible, and, most importantly, lowering blood pressure significantly reduces cardiovascular morbidity and mortality, as proved in clinical trials. The medical and human costs of treating preventable conditions such as stroke, heart failure, and end-stage renal disease can be reduced by antihypertensive treatment. The recurrent and chronic morbidities associated with hypertension are costly to treat. Pharmacotherapy for hypertension therefore offers a substantial potential for cost savings. Pharmacoeconomic analyses regarding antihypertensive drug therapies, their costs, and the relevant reductions in health care expenditures are a useful framework for optimizing current strategies for hypertension management.